Skip to content
OpenCapital
Get started

Recursion Pharmaceuticals, Inc. RXRX Equity incentive plans

Other financials

Income statement

See full
Revenue$6.5M-56.1%
Gross profit-$6.0M+15.0%
Operating income-$128.5M+32.8%
Net income-$117.5M+42.0%
EPS (diluted)-$0.22+56.0%

Balance sheet

See full
Cash & equivalents$665.2M+30.6%
Total debt$88.6M-24.6%
Total equity$1.0B+9.7%
Total assets$1.3B+2.6%

Cash flow

See full
Operating cash flow-$81.1M+38.5%
CapEx$258.0K-85.9%
Free cash flow-$81.4M+39.2%

Valuation

See full
Market cap$1.71B-23.7%
Enterprise value$1.14B-39.8%
P/S25.8×-11.8×

Profitability

See full
Gross margin7.2%—
Operating margin-881.3%-66.8pp
Net margin-842.9%-92.4pp
FCF margin-490.7%-102pp

Returns & leverage

See full
Return on equity-57.2%-14.4pp
Debt / equity0.1×0.0×
Current ratio5.5×+1.4×

Where this comes from

Reported directly by Recursion Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept rxrx:ProceedsFromPaymentForShareBasedPaymentArrangement.

The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Recursion Pharmaceuticals, Inc.'s equity incentive plans.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Recursion Pharmaceuticals, Inc.'s equity incentive plans?
Recursion Pharmaceuticals, Inc. (RXRX) reported equity incentive plans of -$1.26M in Q1 2026.